Evidence map›Paper›PMID 29766807›Full record

ArticleCurrent topics in medicinal chemistry2018

First Total Synthesis of ω-Phenyl Δ6 Fatty Acids and their Leishmanicidal and Anticancer Properties.

Nestor M Carballeira, Christian Morales-Guzman, Ester Alvarez-Benedicto, Zally Torres-Martinez, Yamixa Delgado, Kai H Griebenow, Arthur D Tinoco, Rosa M Reguera, Yolanda Perez-Pertejo, Ruben Carbajo-Andres and 1 more

Abstract read
In one paragraph

Article in Current topics in medicinal chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nestor M CarballeiraDepartment of Chemistry, University of Puerto Rico, San Juan, Puerto Rico.
Christian Morales-GuzmanDepartment of Chemistry, University of Puerto Rico, San Juan, Puerto Rico.
Ester Alvarez-BenedictoDepartment of Chemistry, University of Puerto Rico, San Juan, Puerto Rico.
Zally Torres-MartinezDepartment of Chemistry, University of Puerto Rico, San Juan, Puerto Rico.
Yamixa DelgadoBiochemistry and Pharmacology Department, San Juan Bautista School of Medicine, Caguas, Puerto Rico.
Kai H GriebenowDepartment of Chemistry, University of Puerto Rico, San Juan, Puerto Rico.
Arthur D TinocoDepartment of Chemistry, University of Puerto Rico, San Juan, Puerto Rico.
Rosa M RegueraDepartment of Biomedical Sciences, University of Leon, Campus de Vegazana, 24071, Leon, Spain.
Yolanda Perez-PertejoDepartment of Biomedical Sciences, University of Leon, Campus de Vegazana, 24071, Leon, Spain.
Ruben Carbajo-AndresDepartment of Biomedical Sciences, University of Leon, Campus de Vegazana, 24071, Leon, Spain.
Rafael Balana-FouceDepartment of Biomedical Sciences, University of Leon, Campus de Vegazana, 24071, Leon, Spain.

Funding

Upgrade Laboratories Facilities at UPR-Rio PiedrasR25GM061151 · NIGMS · UNIVERSITY OF PUERTO RICO RIO PIEDRAS · PI CARBALLEIRA, NESTOR MANUEL · 2001 to 2023
$32.5M
RIO PIEDRAS MARC U*STAR DEVELOPMENT PROGRAMT34GM007821 · NIGMS · UNIVERSITY OF PUERTO RICO RIO PIEDRAS · PI CARBALLEIRA, NESTOR MANUEL · 1985 to 2020
$20.3M
Development of Peptide-Conjugate Biomimics for Targeted Ti(IV)-Based Anticancer DSC1CA190504 · NCI · UNIVERSITY OF PUERTO RICO RIO PIEDRAS · PI TINOCO, ARTHUR DAVID · 2014 to 2017
$1.4M
NCI NIH HHS SC1 CA190504NIGMS NIH HHS R25 GM061151NIGMS NIH HHS T34 GM007821
6 · The paper itself

Abstract

introductionThe first total synthesis of ω-phenyl Δ6 fatty acids (FA) and their cytotoxicity (A549) and leishmanicidal (L. infantum) activities are described. The novel 16-phenyl-6-hexadecynoic acid (1) and the known 16-phenylhexadecanoic acid (2) were synthesized in 7-8 steps with overall yields of 46 % and 41 %, respectively. The syntheses of the unprecedented 10-phenyl-6-decynoic acid (3), 10-cyclohexyl-6-decynoic acid (4) and 10-(4-methoxyphenyl)-6-decynoic acid (5) was also performed in 3 steps with 73-76 % overall yields. The use of lithium acetylide coupling enabled the 4-step synthesis of 10-phenyl-6Z-decenoic acid (6) with a 100 % cis-stereochemistry. The cytotoxicity of these novel FA was determined against A549 cells and L. infantum promastigotes and amastigotes. Among the ω-phenylated FA, the best cytotoxicity towards A549 was displayed by 1, with an IC50 of 18 ± 1 μM. On the other hand, among the C10 acids, the ω-cyclohexyl acid 4 presented the best cytotoxicity (IC50 = 40 ± 2 μM) towards A549.

resultsBased on caspase-3/7 studies neither of the FA induced apoptosis in A549, thus implying other mechanisms of cell death.

conclusionThe antileishmanial studies were performed with the top Leishmania donovani topoisomerase IB (LdTopIB) inhibitors, namely 1 and 2 (EC50 between 14 and 36 μM, respectively), acids that did not stabilize the cleavage complexes between LdTopIB and DNA. Acids 1 and 2 displayed cytotoxicity towards L. infantum amastigotes (IC50 = 3-6 μM) and L. infantum promastigotes (IC50 = 60- 70 μM), but low toxicity towards murine splenocytes. Our results identified 1 as the optimum ω- phenylated acid of the series.

Indexed as

Antineoplastic AgentsAntiprotozoal AgentsCell Line, TumorCell ProliferationCell SurvivalDNA Topoisomerases, Type IDose-Response Relationship, DrugDrug Screening Assays, AntitumorFatty Acids, Omega-6HumansLeishmania infantumMolecular StructureParasitic Sensitivity TestsRecombinant ProteinsStructure-Activity RelationshipTopoisomerase I InhibitorsAntineoplastic AgentsAntiprotozoal AgentsDNA Topoisomerases, Type IFatty Acids, Omega-6Recombinant ProteinsTopoisomerase I InhibitorsAcetylenic Fatty AcidsCancerLeishmania infantumLeishmaniasisSynthesisTopoisomerase IB.

Identifiers

PMID29766807
PMCPMC6994230

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.